Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Cash from Financing Activities (2018 - 2026)

DiaMedica Therapeutics filings provide 9 years of Cash from Financing Activities readings, the most recent being $417000.0 for Q1 2026.

  • Quarterly Cash from Financing Activities rose 358.24% to $417000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $44.2 million through Mar 2026, up 265.73% year-over-year, with the annual reading at $43.9 million for FY2025, 265.82% up from the prior year.
  • Cash from Financing Activities hit $417000.0 in Q1 2026 for DiaMedica Therapeutics, down from $12.1 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $36.8 million in Q2 2023 and bottomed at -$6000.0 in Q3 2023.
  • Average Cash from Financing Activities over 5 years is $5.5 million, with a median of $91000.0 recorded in 2025.
  • Peak annual rise in Cash from Financing Activities hit 1842600.0% in 2023, while the deepest fall reached 200.0% in 2023.
  • DiaMedica Therapeutics' Cash from Financing Activities stood at -$1000.0 in 2022, then changed by 0.0% to -$1000.0 in 2023, then skyrocketed by 12100.0% to $120000.0 in 2024, then surged by 9975.83% to $12.1 million in 2025, then crashed by 96.55% to $417000.0 in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Cash from Financing Activities are $417000.0 (Q1 2026), $12.1 million (Q4 2025), and $31.5 million (Q3 2025).